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Tumor gene therapy with the aim of
specifically attacking the malignant cells
takes direct advantage of our current
understanding of carcinogenesis at the
molecular level. This modern treatment
option is largely based on the tremen-
dous efforts that have been made in
identification, cloning, sequencing and
functional analysis of oncogenes during
the last 20 years. In 1982, the develop-
ment of the NIH 3T3 cell transfection
assay made it possible, for the first time,
to identify activated oncogenes in human
tumors. With it, the ras genes were iden-
tified and subsequent work showed that
ras genes encode a family of 21 kDa
intracellular guanosine triphosphate
(GTP) binding proteins. They are integral
to cellular signal transduction and ulti-
mately regulate differentiation, prolifera-
tion, survival and migration in a wide
diversity of cell types. Ras cycles
between its activated GTP-bound form
and its inactive guanosine diphosphate
(GDP)-bound form. A long-standing puz-
zle surrounding p21 ras proteins (there
are 3 functional proteins, H-ras, K-ras,
and N-ras) stems from the amazingly
complex signaling network in which ras
acts as a central player and is itself regu-
lated through the control of the
GTP/GDP cycling rate by GTPase-acti-
vating proteins (GAPs) and guanine
nucleotide exchange factors (GEFs)
(Bar-Sagi and Hall, 2000; Campbell et
al., 1998).
In view of the central role of ras in
cell signaling, it is perhaps not surprising
that ras is one of the most commonly
mutated oncogenes in human malignan-
cies, accounting for about 30%–50% of
human cancer. These ras mutations,
often found in codons 12, 13, 60, and 61,
result in its constitutive activation due to
inability of the ras-bound GTP to be
hydrolyzed to GDP (Bos, 1989). For
many years there has been some hope
that appropriate molecular therapy can
be designed to attenuate ras activity.
Accordingly, ras genes were among the
first targets for which antisense strate-
gies were applied. Despite encouraging
results in preventing tumor growth in ani-
mals, the clinical phase I/II studies with
antisense DNA oligonucleotides against
ras did not ultimately enter into larger
clinical treatment protocols. One major
problem in designing a sequence-specif-
ic anti-ras therapy simply lies in the
nature of its activation: a single point
mutation suffices to turn the protein on
and convert it to a dominant oncoprotein
(Figure 1). Thus, wild-type ras and its
oncogenic form differ only very slightly
with regard to their DNA sequence but
enormously in their biochemical conse-
quences.
In the current issue of Cancer Cell,
Brummelkamp et al. now open a new
chapter in anti-ras-mediated tumor ther-
apy (Brummelkamp et al., 2002b).
Moreover, their approach may generally
serve as a new prototype for blocking
oncogene expression in human can-
cer—the use of RNA interference
(RNAi). It was only one year ago that the
Tuschl group published their pioneering
paper in which they showed how small
double-stranded RNA molecules (small
interfering RNA, siRNA) silence gene
expression in mammalian cell culture
(Elbashir et al., 2001). Since then,
siRNAs, either chemically synthesized or
intracellularly expressed via a poly-
merase III-based transcription system,
have been widely used for targeting
genes in cell culture (Paddison et al.,
2002; Brummelkamp et al., 2002a).
Employing a method similar to that in a
recent report about the application of a
retroviral expression cassette for induc-
tion of RNAi (Paddison and Hannon,
2002), Brummelkamp et al. used a ret-
roviral version of their plasmid vector
system “pSUPER” (suppression of
endogenous RNA). With it, they strongly
inhibited the expression of mutated 
K-rasV12 while leaving other ras isoforms
unaffected. This extraordinary sequence
specificity of RNAi, which clearly ex-
ceeds that of DNA antisense app-
roaches, makes it a very attractive tool
for cancer therapy. Moreover, in a set 
of elegantly performed experiments,
Brummelkamp et al. demonstrated the
power of RNAi-mediated gene therapy
not only in cell culture but, encouraging-
ly, in an animal model as well. The latter
finding, together with two recent reports
about the successful application of RNAi
in mice (Lewis et al., 2002; McCaffrey et
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A little more than one year after the first demonstration that silencing of endogenous human genes is possible in cell 
culture, the new tool of RNA interference (RNAi) enters the field of tumor therapy.
Figure 1. Different mechanisms of oncogene
activation in human tumors
In cancer cells, proto-oncogenes have fre-
quently been activated by various mecha-
nisms, producing oncogenes that act in a
dominant fashion. In epithelial tumors, point
mutations are predominant whereas hema-
tological malignancies often show gene
fusions that result from chromosomal translo-
cations.
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al., 2002), foretells further studies in
which transgenic or knock-in mice carry-
ing such oncogenic alleles will by treated
by RNA-based therapeutics.
Besides point mutations, oncogenes
can be activated by either gene amplifi-
cation or chromosomal translocation fus-
ing two parts of unrelated genes to form
a chimera (Figure 1).The classical proto-
type for gene amplification is the N-MYC
oncogene, which is amplified e.g., in
neuroblastomas, especially at late
stages or in very aggressive types of the
tumor. Whether and how the RNAi
approach can be successfully applied to
target amplified oncogenes in human
tumors remains to be seen. Obviously,
the question is whether the lack of
sequence variation between the activat-
ed (amplified) oncogene and its normal
counterpart in nonmalignant cells caus-
es difficulties with regard to specificity.
What about RNAi for targeting oncogenic
activation by chromosomal transloca-
tion? Recent data from our laboratory
suggest that RNAi can also serve as a
tool to downregulate chimeric fusion
transcripts (Wilda et al., 2002). Leukemic
cells with translocation t(9;22) depend
on the presence of BCR/ABL oncopro-
tein and consequently undergo apopto-
sis when depleted of it.
Nevertheless, some clinicians may
still have doubts as to whether RNAi will
be given a place in the field of cancer ther-
apy. Initially, there is much enthusiasm
about a postgenomic wave of tyrosine-
kinase inhibitors, which undoubtedly have
the potential to change the treatment of
cancer in the future (Shawver et al.,
2002). Although success has already
been achieved in clinical studies with
Trastuzumab and Imatinib mesylate
(STI571) in patients with breast cancer or
Philadelphia chromosome-positive leu-
kemias, respectively, these are only the
first steps on the way to rationally
designed target-directed therapies.
With regard to ras, farnesyltransferase
inhibitors impede oncogenic ras function
by inhibition of its posttranslational modifi-
cations and have already entered numer-
ous clinical trials (Reuter et al., 2000).
Thus, it has to be shown that RNAi-based
therapies are as efficacious as small mol-
ecule drugs or monoclonal antibodies in
targeting kinase enzymes. Second, the
main challenge to any gene therapy must
also be overcome with RNAi: the double-
stranded RNA or the expression vector
encoding such molecules needs to reach
the tumor cells efficiently. The neutraliza-
tion of small interfering RNAs by the
immune system may also be a foresee-
able problem. Third, the advantageous
extreme sequence specificity of RNAi
may, in turn, form the basis for cancer
cells to escape the RNAi-mediated attack.
A single point mutation in the targeted
region abolishes mRNA degradation and
may cause RNAi-resistance in tumors.
Recently we had to learn a similar lesson
from patients who became resistant to the
tyrosine kinase inhibitor STI571 by a vari-
ety of mechanisms including point muta-
tions in the kinase domain (Shah et al.,
2002; Gorre et al., 2001). Thus, to some
extent RNAi-based approaches compete
with the kinase inhibitors in the field of
molecular therapy. But as is often the
case with competitors in the same field: it
may be that only their combined efforts
will help to overcome the numerous prob-
lems associated with drug resistance 
in cancer treatment. The report by
Brummelkamp et al. clearly demonst-
rates the promising power of RNAi for
therapeutic purposes and gives new
hope that a potent tool for the reversion of
an oncogenic phenotype is now in our
hands.
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